Mizuki Yamane

Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models

M. Suzuki, Minako Takeda, A Kito et al. · Nutrition and Diabetes · 2014 · 97 citations · Full text

Stronger Uricosuric Effects of the Novel Selective URAT1 Inhibitor UR-1102 Lowered Plasma Urate in Tufted Capuchin Monkeys to a Greater Extent than Benzbromarone

Sung-Shin Ahn, S. Ohtomo, Jumpei Kiyokawa et al. · Journal of Pharmacology and Experimental Therapeutics · 2016 · 60 citations

Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats

Takumi Nagata, Masanori Fukazawa, Kiyofumi Honda et al. · American Journal of Physiology-Endocrinology and Metabolism · 2012 · 44 citations

Glucose Titration, Renal Inflammation, Metabolic Syndrome +19

<i>In vitro</i>profiling of the metabolism and drug–drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYP

Mizuki Yamane, Kosuke Kawashima, Koji Yamaguchi et al. · Xenobiotica · 2014 · 24 citations

A New Anti-diabetic Zn(II)–Hinokitiol (β-Thujaplicin) Complex with Zn(O4) Coordination Mode

Mizuki Yamane, Yusuke Adachi, Yutaka Yoshikawa et al. · Chemistry Letters · 2005 · 24 citations

Insulin Resistance, Inorganic Chemistry, Medicinal Chemistry +12